BRPI0808763A2 - Compostos para o tratamento de hepatite c - Google Patents

Compostos para o tratamento de hepatite c Download PDF

Info

Publication number
BRPI0808763A2
BRPI0808763A2 BRPI0808763-6A BRPI0808763A BRPI0808763A2 BR PI0808763 A2 BRPI0808763 A2 BR PI0808763A2 BR PI0808763 A BRPI0808763 A BR PI0808763A BR PI0808763 A2 BRPI0808763 A2 BR PI0808763A2
Authority
BR
Brazil
Prior art keywords
alkyl
formula
cyclohexyl
hcv
methoxy
Prior art date
Application number
BRPI0808763-6A
Other languages
English (en)
Portuguese (pt)
Inventor
G. Gentles Robert
Zheng Xiaofan
Ding Min
Tu Yong
Han Ying
Hewawasam Piyasena
F. Kadow John
A. Bender John
Yeung Kap-Sun
A. Grant-Young Katharine
W. Hudyma Thomas
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BRPI0808763A2 publication Critical patent/BRPI0808763A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0808763-6A 2007-03-14 2008-03-05 Compostos para o tratamento de hepatite c BRPI0808763A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89488707P 2007-03-14 2007-03-14
US60/894,887 2007-03-14
US98947407P 2007-11-21 2007-11-21
US60/989,474 2007-11-21
PCT/US2008/055893 WO2008112473A1 (en) 2007-03-14 2008-03-05 Compounds for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
BRPI0808763A2 true BRPI0808763A2 (pt) 2014-09-16

Family

ID=39477552

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808763-6A BRPI0808763A2 (pt) 2007-03-14 2008-03-05 Compostos para o tratamento de hepatite c

Country Status (19)

Country Link
US (1) US7547690B2 (enExample)
EP (1) EP2118109B1 (enExample)
JP (1) JP5232178B2 (enExample)
KR (1) KR20100015304A (enExample)
CN (1) CN101657455B (enExample)
AR (1) AR065772A1 (enExample)
AU (1) AU2008226639B2 (enExample)
BR (1) BRPI0808763A2 (enExample)
CA (1) CA2681093A1 (enExample)
CL (1) CL2008000751A1 (enExample)
CO (1) CO6180426A2 (enExample)
EA (1) EA016614B1 (enExample)
IL (1) IL200905A0 (enExample)
MX (1) MX2009009473A (enExample)
NZ (1) NZ579342A (enExample)
PE (1) PE20090648A1 (enExample)
TW (1) TW200848058A (enExample)
WO (1) WO2008112473A1 (enExample)
ZA (1) ZA200906129B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688420A4 (en) * 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2009067108A1 (en) * 2007-11-20 2009-05-28 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
WO2009080836A2 (en) 2007-12-24 2009-07-02 Tibotec Pharmaceuticals Ltd. Macrocyclic indoles as hepatitis c virus inhibitors
JP2011515484A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ピロリジン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
MX2010010061A (es) * 2008-03-27 2010-09-30 Bristol Myers Squibb Co Compuestos para el tratamiento de hepatitis c.
US8138171B2 (en) * 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
RU2012128583A (ru) * 2009-12-07 2014-01-20 Таргасепт, Инк. 3,6-диазабицикло[3.1.1]гептаны в качестве лигандов нейрональных никотиновых ацетилхолиновых рецепторов
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
WO2014011863A1 (en) * 2012-07-12 2014-01-16 Targacept, Inc. Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
HK1210770A1 (en) * 2012-07-18 2016-05-06 Bristol-Myers Squibb Holdings Ireland Unlimited Company Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
ES2775782T3 (es) 2016-03-15 2020-07-28 Bayer Cropscience Ag Sulfonilamidas sustituidas para combatir parásitos animales
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN110028510A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法
KR20220098170A (ko) 2019-11-07 2022-07-11 바이엘 악티엔게젤샤프트 동물 해충 방제를 위한 치환된 술포닐 아미드
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206715A1 (en) 2004-02-24 2010-07-14 Japan Tobacco, Inc. Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007119562A (ru) 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2029606B1 (en) * 2006-05-25 2010-05-26 Brystol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Also Published As

Publication number Publication date
KR20100015304A (ko) 2010-02-12
TW200848058A (en) 2008-12-16
CL2008000751A1 (es) 2008-07-25
AU2008226639B2 (en) 2012-07-19
AU2008226639A1 (en) 2008-09-18
CN101657455B (zh) 2013-02-06
US20080227769A1 (en) 2008-09-18
PE20090648A1 (es) 2009-05-29
ZA200906129B (en) 2010-11-24
JP2010521476A (ja) 2010-06-24
WO2008112473A1 (en) 2008-09-18
MX2009009473A (es) 2009-09-15
EP2118109A1 (en) 2009-11-18
EP2118109B1 (en) 2014-11-26
CN101657455A (zh) 2010-02-24
US7547690B2 (en) 2009-06-16
AR065772A1 (es) 2009-07-01
IL200905A0 (en) 2010-05-17
EA200901241A1 (ru) 2010-02-26
JP5232178B2 (ja) 2013-07-10
NZ579342A (en) 2011-07-29
CA2681093A1 (en) 2008-09-18
EA016614B1 (ru) 2012-06-29
CO6180426A2 (es) 2010-07-19

Similar Documents

Publication Publication Date Title
BRPI0808763A2 (pt) Compostos para o tratamento de hepatite c
ES2397740T3 (es) Compuestos para el tratamiento de la hepatitis C
ES2375065T3 (es) Inhibidores de indilobenzazepina condensada con ciclopropilo de la ns5b del vhc.
ES2390191T3 (es) Inhibidores de VHC de indolobenzazepina condensada con ciclopropilo
EP2121697B1 (en) Compounds for the treatment of hepatitis c
EP2518073B1 (en) Compounds for the treatment of Hepatitis C
ES2362560T3 (es) Derivados de indolobenzazepina condensados con ciclopropilo para el tratamiento de la hepatitis c.
NZ572555A (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
ES2370121T3 (es) Compuestos para el tratamiento de la hepatitis c.
ES2360737T3 (es) Inhibidores de ns5b del vhc de indolobenzazepina condensados con ciclopropilo.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2367 DE 17-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.